Delivery Order SPE2DR25D1017-SPE2DR26F8YNP
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,413.60 on August 25, 2025, for the supply of Xcopri 200 mg tablets (30-count). The contract is classified as a firm fixed price delivery order with an ultimate completion date of August 26, 2025, and represents a non-competitive set-aside award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is the place of performance for this order. This delivery order is issued under the company's...
- The Defense Logistics Agency awarded a $1,227.16 delivery order to AmerisourceBergen Drug Corp on October 27, 2025, for the supply of Xcopri 150 mg tablets (30-count units). This firm fixed-price, non-set-aside contract is classified as a child award under a larger indefinite delivery contract vehicle and represents a routine pharmaceutical procurement supporting federal medical supply needs. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with...
- The Defense Logistics Agency awarded a delivery order valued at $3,967.00 to AmerisourceBergen Drug Corp on October 27, 2025, for the supply of Xcopri 100 mg tablets (30-count units). This is a firm fixed price delivery order with a completion date of October 28, 2025, and represents a competitively awarded, non-set-aside contract. The award is performed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Xcopri 100 mg tablets (30-count packaging) with a ceiling value of $1,178.96. This firm fixed-price delivery order, which is not set-aside, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The order will be fulfilled from the...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,080.32 on September 2, 2025, for the supply of Xcopri 200 mg tablets (30-count units). This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the Conshohocken, Pennsylvania-based pharmaceutical distributor. The contract was issued as a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99...
- The Defense Logistics Agency awarded a $3,536.88 delivery order to AmerisourceBergen Drug Corp on May 13, 2025, for the supply of Xcopri 100 mg tablets (30-count units). This firm fixed-price, non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The pharmaceutical product will be delivered to the company's corporate office location in...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,396.12 to AmerisourceBergen Drug Corp for the supply of Xcopri 50 mg tablets (30-count units). This competitively awarded, firm fixed price delivery order was issued on August 18, 2025, with an ultimate completion date of August 19, 2025. The pharmaceutical products will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a discrete transaction under...
- The Defense Logistics Agency awarded a delivery order valued at $3,042.04 to AmerisourceBergen Drug Corp for the supply of Xcopri 50 mg tablets (30-count packages) under a firm fixed-price contract. The delivery order was competitively awarded without set-aside designations and carries an ultimate completion date of October 20, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 22, 2025, for the supply of Xcopri 50 mg tablets (30-count units) under a firm fixed-price contract valued at $19,386.20. This is a non-set-aside award with an ultimate completion date of October 23, 2025, and performance occurring at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order serves as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Xcopri 25 mg tablets (30-unit packaging), with a contract ceiling value of $1,768.44. This is a firm fixed price delivery order with an ultimate completion date of August 14, 2025, and represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child...
- SPE2DR25D1017Indefinite Delivery Contract
- SPE2DR25D1017-SPE2DR26F8YNPDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 27, 2025, for the supply of Xcopri 150 mg tablets (30-count units) with a ceiling value of $1,149.54. This firm fixed-price delivery order, which is expected to be completed by October 28, 2025, represents a non-set-aside competitive award. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under a larger Indefinite Delivery Contract vehicle—the DLA Troop Support Medical contract (SPE2DX)—valued at $999,999,999.00 and extending through December 2026, which serves as a comprehensive global pharmaceutical supply agreement for military healthcare operations worldwide. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that fulfills critical medical procurement needs for federal agencies, particularly the Department of Defense and military healthcare systems. As a primary vendor within the DLA's Medical Supply Chain, the company supplies a broad portfolio of pharmaceutical products including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. The company's track record demonstrates consistent capability to meet federal procurement requirements through open competition, with this delivery order exemplifying its role in supporting the ongoing pharmaceutical needs of the military and veteran healthcare infrastructure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 10/27/25 |